| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8778264 | European Urology | 2018 | 13 Pages |
Abstract
There are many treatment options for patients diagnosed with metastatic renal cell carcinoma. We indirectly compared the available options and found that cabozantinib and nivolumab plus ipilimumab are likely to be preferable choices as the first-line treatment in this situation.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, Xiang Y. Ye, Thenappan Chandrasekar, Ann M. Farrell, Hanan Goldberg, Stephen A. Boorjian, Bradley Leibovich, Girish S. Kulkarni, Prakesh S. Shah, Georg A. Bjarnason, Daniel Y.C. Heng,